<DOC>
	<DOCNO>NCT00247728</DOCNO>
	<brief_summary>The purpose study evaluate efficacy PI-88 inhibit reduce tumor recurrence patient hepatocellular carcinoma follow hepatectomy .</brief_summary>
	<brief_title>PI-88 Hepatocellular Carcinoma After Hepatectomy</brief_title>
	<detailed_description>Although early diagnosis treatment improve survival , hepatocellular carcinoma ( HCC ) rarely cure recurs frequently regional therapy transplantation . Hepatic resection improve 5-year recurrence-free survival 25 % . Micrometastases HCC detect molecular technique 88 % patient time surgery , probably cause postoperative recurrence . Efforts reduce risk recurrence curative resection try , include various regimen adjuvant neoadjuvant therapy . In study , anti-angiogenic agent , PI-88 , use adjuvant therapy HCC patient curative hepatic resection . The efficacy endpoint , include tumour non-recurrence rate , time first recurrence 1-year survival rate evaluate . Several risk factor associate tumour recurrence also analyse . There two stage study . In stage 1 three arm - untreated control two arm two different PI-88 dose . In stage 2 good two PI-88 arm continue control arm .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<criteria>Patients voluntarily give write informed consent Age ≥ 18 year ≤ 75 year Males females Histological diagnosis hepatocellular carcinoma Curative hepatectomy within past 46 week ECOG performance status 0 2 Cardiac functional capacity ≤ class II ( New York Heart Association ) Patients adequate renal , hepatic , haematopoietic function define : Serum creatinine ≤ 2.0 mg/dL Total bilirubin &lt; 2.5 mg/dL Neutrophil count &gt; 1.5 x 10^9/L ALT &lt; 5 x upper limit normal ( ULN ) White blood cell ( WBC ) count ≥ 3 x 10^9/L Platelet count ≥ 80 x 10^9/L Prothrombin time international normalize ratio ( PTINR ) ≤ 1.3 ( PTINR ≤ 1.4 PT within normal range ) Activated partial thromboplastin time ( APTT ) &lt; ULN Patients history allergy and/or hypersensitivity anticoagulants/thrombolytic agent , especially heparin . Patients history immune mediate thrombocytopenia , thrombotic thrombocytopenic purpura , platelet disease Patients previous positive result heparininduced thrombocytopenia ( HIT ) antibody test . Patients tumour metastasis . Patients uncontrolled infection serious infection within past 4 week . Patients myocardial infarction , stroke , congestive heart failure within past 3 month . Patients history inflammatory bowel disease , abnormal bleeding tendency , patient risk bleed due open wound plan surgery . Patients acute chronic gastrointestinal bleeding within past 1 year . Patients history drug abuse psychiatric disorder . Patients know HIV infection AIDSrelated illness . Patients receive investigational antineoplastic medication within past 4 week . Use aspirin , aspirincontaining medication , nonsteroidal antiinflammatory drug ( except COX2 inhibitor ) , heparin , low molecular weight heparin , warfarin , antiplatelet drug , anticoagulant medication 2 week prior study period . Women pregnant breastfeeding . Women childbearing potential use adequate method contraception .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2007</verification_date>
	<keyword>PI-88</keyword>
	<keyword>post resection hepatoma</keyword>
	<keyword>adjuvant therapy</keyword>
	<keyword>hepatectomy</keyword>
	<keyword>hepatoma</keyword>
</DOC>